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Toll-like receptors (TLRs) recognize microbial pathogens and trigger innate immune 
responses. Among TLR family members, TLR7, TLR8, and TLR9 induce interferon (IFN)-
 
 
 
 
in plasmacytoid dendritic cells (pDCs). This induction requires the formation of a complex 
consisting of the adaptor MyD88, tumor necrosis factor (TNF) receptor-associated factor 6 
(TRAF6) and IFN regulatory factor (IRF) 7. Here we show an essential role of IL-1 receptor-
associated kinase (IRAK)-1 in TLR7- and TLR9-mediated IRF7 signaling pathway. IRAK-1 
directly bound and phosphorylated IRF7 in vitro. The kinase activity of IRAK-1 was necessary 
for transcriptional activation of IRF7. TLR7- and TLR9-mediated IFN-
 
 
 
 production was 
abolished in 
 
Irak
 
-
 
1
 
–deficient mice, whereas inflammatory cytokine production was not 
impaired. Despite normal activation of NF-
 
 
 
B and mitogen-activated protein kinases, IRF7 
was not activated by a TLR9 ligand in 
 
Irak-1
 
–deficient pDCs. These results indicated that 
IRAK-1 is a specific regulator for TLR7- and TLR9-mediated IFN-
 
 
 
 induction in pDCs.
 
Toll-like receptors (TLRs) play a critical role
in innate immune responses in mammals (1,
2). So far, 11 members of the TLR family
(TLR1–11) have been identified (3). Among
these members, TLR7, TLR8, and TLR9
have closely related molecular structures and
exert similar immune responses by recognizing
nucleic acid ligands (4). TLR7 and TLR8
recognize single-stranded (ss) RNA and imi-
dazoquinolines, and TLR9 recognizes CpG
oligodeoxynucleotides (CpG ODN) as well as
certain microbial DNA (5–10). Upon binding
of their ligands, TLR7 and TLR9 recruit a
Toll–IL-1 receptor (TIR) domain-containing
adaptor MyD88. Then, MyD88 associates
with IL-1 receptor-associated kinase (IRAK)
family members through the homophilic inter-
action between their death domains. TNF
receptor-associated factor 6 (TRAF6) is also
recruited and NF-
 
 
 
B and mitogen-activated
protein kinases (MAPKs) are finally activated.
These events result in induction of inflamma-
tory cytokines such as TNF-
 
 
 
, IL-6, IL-1
 
 
 
,
and IL-12 (3). This is a common pathway for
TLR signaling, which is called the MyD88-
dependent pathway (2).
There are four IRAK family members in-
cluding IRAK-1, IRAK-2, IRAK-M, and
IRAK-4 (11–14). Among them, only IRAK-1
and IRAK-4 possess intrinsic serine/threonine
kinase activity (15). IRAK-1 was reported as a
kinase critically involved in IL-1R signaling in
vitro (16, 17). IL-1–mediated IL-6 production
as well as activation of MAPKs and NF-
 
 
 
B
were reduced in 
 
Irak-1
 
 
 
/
 
 
 
 embryonic fibro-
blasts (EFs; 14, 18). However, macrophages
from 
 
Irak-1
 
 
 
/
 
 
 
 mice showed only partial im-
pairment of cytokine production as well as
NF-
 
 
 
B activation in response to TLR ligand
(19). In contrast, 
 
Irak-4
 
 
 
/
 
 
 
 mice exhibited se-
vere impairment in response to IL-1, IL-18, or
ligands of various TLRs (20). This phenotype
is quite similar to that of 
 
Myd88
 
 
 
/
 
 
 
 mice.
Thus, IRAK-4 is thought to be essential for
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the MyD88-dependent pathway. In vitro experiments
showed that IRAK-1 is phosphorylated and activated by
IRAK-4 (12, 20). However, the relationship between IRAK-1
and IRAK-4 and the requirement of the kinase activity of
IRAKs in various signaling events are still unclear (21, 22).
In addition to production of inflammatory cytokines,
ligand stimulation of TLR7, TLR8, and TLR9 can induce
IFN-
 
 
 
 in a special subset of DCs, pDCs (8, 9, 23, 24). This
unique subset of DCs is known for their ability to produce a
large amount of type I IFNs upon viral infection (25–27).
IFN-
 
 
 
 induction in response to these TLR ligands is abol-
ished in 
 
MyD88
 
 
 
/
 
 
 
 pDCs (24), suggesting that TLR7,
TLR8, and TLR9 have a unique mechanism that activates the
genes encoding IFN-
 
 
 
 in a MyD88-dependent manner in
pDCs. Our recent study showed that TLR7- and TLR9-
mediated IFN-
 
 
 
 induction requires the formation of a com-
plex consisting of MyD88, TRAF6, and IRF7 (28). Activated
IRF7 in the complex translocates into the nucleus, and induce
transcription of type I IFN genes. More recently, Honda et al.
reported that IFN-
 
 
 
 production by TLR7 and TLR9 ligands
was abolished in splenic pDCs derived from 
 
Irak-4
 
 
 
/
 
 
 
 mice
(29). Although IRAK-1 has been considered to work down-
stream of MyD88, the role of IRAK-1 in the TLR7- and
TLR9-mediated IFN-
 
 
 
 production remains to be seen.
Here we examined a role of IRAK-1 in TLR7- and
TLR9-mediated signaling pathways. IRAK-1 associated
with and phosphorylated IRF7 in vitro, indicating that
IRAK-1 was also involved in the complex composed of
MyD88 and TRAF6. Severely impaired production of IFN-
 
 
 
in response to TLR7 and TLR9 ligands was observed in
 
Irak-1
 
 
 
/Y
 
 mice. On the other hand, production of inflamma-
tory cytokines by TLR7 and TLR9 ligands was not im-
paired. IRF7 failed to translocate to the nucleus in response
to TLR9 ligand in 
 
Irak-1
 
 
 
/Y
 
 pDCs, indicating that IRAK-1
is prerequisite for the activation of IRF7. Taken together,
IRAK-1 is a molecule specifically involved in the induction
of IFN-
 
 
 
 by TLR7 and TLR9 ligands.
 
RESULTS
IRAK-1 associates with IRF7
 
In a previous study, we showed that IRF7 forms a com-
plex with MyD88 and TRAF6 to induce IFN-
 
  
 
(28). Be-
cause IRAK-1 and IRAK-4 were shown to associate with
MyD88, we investigated whether IRAK-1 and IRAK-4
were involved in IRF7 complex. We first analyzed the inter-
action of IRF7 with IRAK-1 or IRAK-4 by coimmunopre-
cipitation experiments. When human embryonic kidney
(HEK) 293 cells were transiently transfected with a plas-
mid encoding FLAG-tagged IRF7 along with Myc-tagged
IRAK-1 or IRAK-4, FLAG–IRF7 was coprecipitated with
anti-Myc in cells expressing Myc–IRAK-1 but not Myc–
IRAK-4 (Fig. 1 A). This indicates that IRAK-1 but not
IRAK-4 interacts with IRF7. We further analyzed the phys-
ical interaction of IRAKs and IRF7 in live cells. We trans-
fected HEK293 cells with yellow fluorescent protein (YFP)-
labeled IRF7 and cyan fluorescent protein (CFP)–labeled
IRAK-1 or CFP-labeled IRAK-4, and then visualized these
by inverted fluorescence microscopy. IRF7–YFP was dif-
fusely expressed in the cytoplasm when coexpressed with
IRAK-4–CFP. On the contrary, when coexpressed with
IRAK-1–CFP, IRF7–YFP was expressed as a condensed
form with IRAK-1–YFP in the cytoplasm (Fig. 1 B). When
we analyzed these cells for physical interaction between
IRF7-YFP and IRAK-1–CFP or IRAK-4–CFP, we de-
tected a strong fluorescence resonance energy transfer
(FRET) signal from IRF7 in the area merged with IRAK-1
but not IRAK-4 (Fig. 1 B). We also found identical colocal-
ization and physical interaction when we transfected cells
with IRF7-CFP and IRAK-1–YFP (unpublished data). We
further confirmed this observation by measuring FRET by
using flow cytometry (28). When HEK293 cells were trans-
fected with IRF7–YFP and IRAK-1–CFP or IRAK-4–
CFP, only cells that expressing IRF7 with IRAK-1 but not
IRAK-4 showed a strong FRET signal, suggesting that IRF7
interacts directly with IRAK-1 but not IRAK-4 in the cyto-
plasm in live cells (Fig. 1 B). Reciprocally, a similar result
Figure 1. IRAK-1 but not IRAK-4 associates with IRF7. (A) HEK293 
cells were transiently transfected with FLAG–IRF7 together with Myc–IRAK–1 
or Myc-IRAK-4. Cell lysates were immunoprecipitated (IP) with an anti-Myc 
or anti-FLAG, followed by immunoblot (IB) analysis using anti-FLAG or 
anti-Myc, as indicated. Slowly migrated forms of FLAG–IRF7 were shown 
by an asterisk. (B, top) HEK293 cells were transfected with IRF7-YFP (yellow) 
and IRAK-1–CFP or IRAK-4–CFP (blue) and physical interaction of these two 
molecules determined by FRET (pseudocolor) was visualized. (B, bottom) 
HEK293 cells were transfected with IRF7-YFP, IRAK-1-CFP, or IRAK-4-CFP. 
(Left) Fluorescence intensity of CFP emission by CFP excitation of single 
cells (horizontal axis) and YFP emission by CFP excitation of single cells 
(vertical axis). Cells that are positive for both YFP and CFP by CFP excita-
tion are shown in gated area as FRET. (Right) Calculated FRET of IRAK-1–
CFP or IRAK-4–CFP and IRF7–YFP. (C) Cell lysates prepared from HEK293 
cells transiently transfected with a combination of FLAG–IRF7 deletion 
mutants and Myc–IRAK-1 were immunoprecipitated with an anti-Myc or 
anti-FLAG, followed by immunoblot analysis using anti-FLAG or anti-Myc, 
as indicated. 
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was obtained when cells were introduced with IRF7–CFP
and IRAK-1–YFP (unpublished data).
We next examined which portion of IRF7 is responsible
for interaction with IRAK-1. HEK293 cells were transiently
transfected with Myc–IRAK-1 together with FLAG–IRF7
or deletion mutants of FLAG–IRF7 encoding amino acids
1–285 or 1–237. FLAG–IRF7 and FLAG–IRF7 1–285 ex-
pressed in HEK293 cells were coprecipitated with anti-Myc,
showing that the region between amino acids 238 and 285
of IRF7 is required for interaction with IRAK-1 (Fig. 1 C).
This portion of IRF7 was shown previously to be required
for the interaction with both MyD88 and TRAF6, suggest-
ing that IRAK-1 is involved in the complex through the in-
teraction with this portion (28).
 
Kinase activity of IRAK-1
 
IRF7 has been shown to be activated during viral infection by
phosphorylation of the COOH-terminal serine residues and
translocates into nucleus where it regulates the expression of
target genes including IFN-
 
  
 
(30). Therefore, we examined
whether the kinase activity of IRAK-1 is necessary for IRF7
activation. HEK293 cells were transfected with FlAG–IRF7
along with Myc–IRAK-1 or Myc–kinase negative (KN) mu-
tant of IRAK-1 (Myc–IRAK-1 KN). FLAG–IRF7 was then
coprecipitated with anti-Myc in cells expressing both IRAK-1
and IRAK-1 KN (Fig. 2 A). We detected slowly migrating
forms of FLAG–IRF7 in cells expressing Myc–IRAK-1 but
not in cells coexpressing IRAK-1 KN, suggesting that IRAK-1
induces IRF7 phosphorylation through its kinase activity
(Fig. 2 A). To determine whether IRAK-1 could phosphory-
late the COOH terminus of IRF7, we performed in vitro
kinase assay using bacterially expressed GST–IRF7 as a sub-
strate. IRAK-1, IRAK-1 KN, IRAK-4, and IRAK-4 KN
were expressed in HEK293 cells and cell lysates were immu-
noprecipitated with anti-FlAG. Phosphorylation of GST–
IRF7 was found in immunoprecipitates of IRAK-1 but not
IRAK-4 (Fig. 2 B). These data indicate that IRAK-1, but not
IRAK-4, phosphorylates IRF7 in vitro. We next tested
whether the kinase activity of IRAK-1 is necessary for the
transcriptional activity of IRF7. In previous work, we
showed synergistic activation of IFN-
 
 
 
 promoters by coex-
pression of IRF7 and MyD88 (28). However, overexpression
of neither IRAK-1 nor IRAK-4 in combination with IRF7
resulted in any synergistic activation of IFN-
 
 
 
 promoter in
Figure 2. IRF7 activation by IRAK-1. (A) Cell lysates prepared from 
HEK293 cells transiently transfected with FLAG–IRF7 together with Myc–
IRAK1 or Myc–IRAK1 KN were immunoprecipitated with anti-Myc or anti-
FLAG, followed by immunoblot analysis using anti-FLAG or anti-Myc, as 
indicated. (B) HEK293 cells were transiently transfected with FLAG–IRAK-1, 
FLAG–IRAK-1 KN, FLAG–IRAK-4, or FLAG–IRAK-4 KN. Cell lysates were 
immunoprecipitated with anti-FLAG and subjected to in vitro kinase reac-
tion in the presence of GST–IRF7. Proteins were separated on SDS-PAGE, 
followed by visualized by autoradiography. (C) HEK293 cells were tran-
siently transfected with a combination of IRF7, MyD88, and 1, 10, or 50 ng 
of a KN mutant of IRAK-1 (IRAK-1 KN) along with a reporter plasmid car-
rying an IFN- 4 promoter (left). HEK293 cells were also transfected with a 
combination MyD88 and 1, 10, or 50 ng of IRAK-1 KN along with a reporter 
plasmid carrying an ELAM promoter (right). 36 h after transfection, cells 
were analyzed for IFN- 4– or ELAM-dependent promoter activities by a 
reporter gene assay. 
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HEK293 cells (unpublished data). Therefore, we transiently
transfected HEK293 cells with a combination of IRF7,
MyD88 and various amounts of IRAK-1 KN along with a
reporter plasmid carrying the IFN-
 
 
 
4 promoter. IRAK-1
KN inhibited the activation of the IFN-
 
 
 
4 promoter induced
by coexpression of MyD88 and IRF7 in a dose dependent
manner, whereas IRAK-1 KN did not inhibit the NF-
 
 
 
B ac-
tivation by MyD88. Such effects of IRAK-1 KN was in sharp
contrast to a truncated mutant of TRAF6 containing only the
COOH-terminal TRAF domain (TRAF6C), which acts as
dominant negative mutant and interfered the activation of
both IFN-
 
 
 
4 and NF-
 
 
 
B promoters (Fig. 2 C). These data
suggest that IRAK-1 can phosphorylate IRF-7 in vitro and
the kinase activity of IRAK-1 is necessary for the transcrip-
tional activity of IRF7 but not of NF-
 
 
 
B.
 
Response to A/D-type CpG ODN in 
 
Irak-1
 
 
 
/Y
 
 pDCs
 
To elucidate the in vivo role of IRAK-1 in TLR-mediated
IFN-
 
 
 
 production, we examined CpG ODN-induced IFN-
 
 
 
production by using Flt3 ligand (Flt3L)–BM DCs derived
from 
 
Irak-1
 
 
 
/Y
 
 mice. A large amount of IFN-
 
 
 
 production
from 
 
Irak-1
 
 
 
/Y
 
 Flt3L–BMDCs was observed in response to
A/D type CpG ODN, D35 (31). However, the production
of IFN-
 
 
 
 was severely impaired in 
 
Irak-1
 
 
 
/Y
 
 Flt3L–BMDCs.
In contrast, 
 
Irak-1
 
 
 
/Y
 
 and 
 
Irak-1
 
 
 
/Y
 
 Flt3L–BMDCs produced
similar levels of TNF-
 
 
 
, IL-6, and IL-12p40 in response to
D35 (Fig. 3 A). Furthermore, Northern blot analysis revealed
that although induction of IL-6 mRNA was comparable in
 
Irak-1
 
 
 
/Y
 
 Flt3L–BMDCs, IFN-
 
 
 
4 mRNA induction by D35
was also abolished in 
 
Irak-1
 
 
 
/Y
 
 Flt3L–BMDCs (Fig. 3 B).
Culture of BM cells with Flt3L results in the induction of
both pDCs (B220
 
 
 
) and conventional (B220
 
 
 
) DCs (32). Al-
though pDCs are the major source of IFN-
 
 
 
 production,
proinflammatory cytokines such as IL-12 are produced by
both subsets of DCs (4). Because it is difficult to distinguish
whether induction of proinflammatory cytokines was im-
paired in pDCs, we further analyzed the production of IFN-
 
 
 
and IL-12 from B220
 
 
 
 pDCs by flow cytometry. Flt3L–BM–
DCs from 
 
Irak-1
 
 
 
/Y
 
 and 
 
Irak-1
 
 
 
/Y
 
 mice were stimulated with
D35 and stained with antibodies against IFN-
 
 
 
 or IL-12, co-
stained with CD11c and B220. The analysis with flow cytom-
etry revealed that D35-induced production of IFN-
 
 
 
 from
 
Irak-1
 
 
 
/Y
 
 B220
 
  pDCs was severely impaired, compared with
that from Irak-1 /Y B220  pDCs. On the other hand, IL-12
production was not impaired in Irak-1 /Y B220  pDCs (Fig.
3 C). These results indicate that TLR9 ligand–induced IFN- 
production was specifically impaired in Irak-1 /Y pDCs.
Response of Irak-1 /Y cells to other TLR ligands
ODN1668, K-type, or conventional CpG ODN can stimu-
late wild-type Flt3L–BMDCs to produce IFN-  at low con-
centrations between 0.01 and 0.1  M (24), although the max-
Figure 3. Impaired IFN-  induction by D35 in Irak-1-/Y mice. (A) 
Flt3L–BMDCs from Irak-1 /Y and Irak-1 /Y mice were stimulated with the 
indicated concentration of D35 for 24 h. Concentration of IFN- , TNF- , 
IL-6, and IL-12p40 in the culture supernatants were measured by ELISA. 
Data are shown as the mean   SD. (B) Flt3L–BMDCs from Irak-1 /Y and 
Irak-1 /Y mice were stimulated with 1  M D35 for the indicated periods. 
Total RNA was extracted and subjected to Northern blot analysis. (C) Intra-
cellular IFN-  and IL-12 staining of Flt3L–BMDCs derived from Irak-1 /Y 
and Irak-1 /Y mice stimulated with 3  M CpG DNA (D35). CD11c B220  
population of Flt3L–BMDCs was analyzed as pDC, respectively.JEM VOL. 201, March 21, 2005 919
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imal induction is less than that of D35-stimulated DCs. Similar
to the results obtained by A/D type CpG ODN, the produc-
tion of IFN-  in response to ODN1668 were severely im-
paired in Irak-1 /Y Flt3L–BMDCs. However, the productions
of other cytokines, such as TNF- , IL-6, and IL-12 p40 were
comparable between Irak-1 /Yand Irak-1 /Y cells (Fig. 4 A).
As TLR9 ligand–induced IFN-  production was abol-
ished in Irak-1 /Y mice, we also examined TLR7-mediated
IFN-  induction in Irak-1 /Y mice. We intravenously in-
jected  Irak-1 /Yand  Irak-1 /Y mice with TLR7 ligand
R-848 and examined serum concentration of IFN- . Within
an hour after R-848 injection, Irak-1 /Y mice showed in-
creased serum concentrations of IFN- , whereas serum lev-
els of IFN-  did not increase in Irak-1 /Y mice. In contrast,
there was no difference in serum concentrations of IL-12p40
between Irak-1 /Yand Irak-1 /Y mice (Fig. 4 B). These re-
sults suggested that IRAK-1 is involved in TLR7-mediated
IFN-  production as well.
To rule out the possibility of intrinsic defect in IFN- 
production in Irak-1 /  mice, we transfected double stranded
(ds) RNA, poly(I/C) into Flt3-BMDCs derived from Irak-1 /Y
mice and measured IFN-  production. Irak-1 /Y and Irak-1 /Y
Flt3L–BMDCs produced similar levels of IFN-  in response
to poly(I/C) (Fig. 4 C), showing that Irak-1 /Y mice has abil-
ity to produce IFN- . Thus, IRAK-1 is specifically involved
in TLR7- and TLR9-mediated IFN-  production.
Defective activation of IRF7 in Irak-1 /Y cells
We next investigated whether IRF7 is activated by TLR9
ligand in Irak-1 /Y mice. We stimulated Flt3L–BMDCs
from Irak-1 /Y and Irak-1 /Y mice with D35 and analyzed
nuclear proteins by immunoblot analysis with anti-IRF7 or
anti–NF- B, RelA. IRF7 translocated into the nucleus 1 h
after D35 stimulation and diminished at 6 h in Irak-1 /Y
cells. In contrast, IRF7 failed to move into the nucleus in re-
sponse to D35 in Irak-1 /Y cells (Fig. 5 A). RelA translo-
cated into the nucleus in response to D35 both in Irak-1 /Y
and Irak-1 /Y cells although less amount of RelA stayed in
nucleus at later time point in Irak-1 /Y(Fig. 5 A). We also
analyzed the activation of a MAP kinase family member,
ERK1 in response to D35 by immunoblot analysis. Tyrosine
phosphorylation of ERK1 was induced in both Irak-1 /Y
and Irak-1 /Y cells, although the phosphorylation in Irak-1 /Y
cells was slightly more transient than that in Irak-1 /Y cells
(Fig. 5 B). These results indicate that IRAK-1 critically reg-
ulates the activation of IRF7 and is involved in the produc-
tion of IFN-  in response to CpG ODN.
DISCUSSION
IRAK-1 was originally identified as a kinase recruited to the
IL-1R complex after IL-1 treatment (16, 17). In vitro studies
demonstrated that IRAK-1 participates in NF- B activation
of IL-1R–TLR signals (15). In vivo studies using Irak-1 / 
Figure 4. IFN-  induction by other TLR ligands in Irak-1 /Y mice. 
(A) Flt3L–BMDCs from Irak-1 /Y and Irak-1 /Y mice were stimulated with 
the indicated concentration of ODN1668 for 24 h. Concentration of IFN- , 
TNF- , IL-6, and IL-12p40 in the culture supernatants was measured by 
ELISA. Data are shown as the mean   SD. (B) Irak-1 /Y and Irak-1 /Y mice 
(n   3) were intravenously injected with 50 nmol of R-848. Samples of 
sera were taken and the concentrations of IFN-  and IL-12p40 were 
determined by ELISA. (C) Flt3L–BMDCs from Irak-1 /Y and Irak-1 /Y mice 
were transfected with 10  g/ml poly(I/C) for 24 h. Concentration of IFN-  
in the culture supernatants was measured by ELISA. Data are shown as the 
mean   SD. N.D., not detected.IRAK-1 REQUIREMENT FOR TLR7- AND TLR9-MEDIATED IFN-  INDUCTION | Uematsu et al. 920
EFs confirmed that IRAK-1 is essential for IL-1–mediated
IL-6 production as well as activation of MAPKs and NF- B
(14, 18). However, cytokine production as well as NF- B
activation in response to TLR4 ligand, LPS was only par-
tially impaired in Irak-1 /  macrophages (19), suggesting that
IRAK-1 is redundant in the response of certain cell types to
TLR ligands. In this report, we found a novel function of
IRAK-1 in pDCs. IRAK-1 is a regulator essential for IRF7
activation in TLR7 and TLR9 signaling pathways. IRAK-1
was dispensable for TLR9-mediated NF- B and MAP ki-
nase activation as well as proinflammatory cytokine produc-
tion in pDCs. IRAK-1 acts as a gateway for the activation of
IRF7 pathway to induce IFN-  production (Fig. 5 C).
Based on studies in IL-1R signaling pathways, an elabo-
rate model explaining the mechanism of IRAK-1 activation
has been established (15). Upon ligand stimulation, IRAK-1
is recruited to IL-1R and forms a complex with MyD88,
IRAK-4 and TRAF6. It is suggested that IRAK-4 locates up-
stream of IRAK-1 and phosphorylates IRAK-1 in the IL-1R
complex. The phosphorylation triggers the induction of ki-
nase activity of IRAK-1 itself, which results in multiple phos-
phorylation events and increasing its affinity for TRAF6
(33, 34). Because the kinase activity of IRAK-1 is reported to
be dispensable for downstream NF- B activation (35), the
precise role of the kinase activity was still unclear. In TLR7
and TLR9 signaling pathways in pDCs, it is assumed that a
similar receptor complex is formed upon ligand stimulation.
Genetic studies showed that MyD88 and IRAK-4 are essen-
tial for both IFN-  and inflammatory cytokine induction
(29), indicating that these molecules do not determine the
specificity of the signaling. Furthermore, IRAK-4 does not
bind IRF7 directly, suggesting that IRAK-4 acts upstream of
IRAK-1 in the signaling. Taken together, IRAK-4 may par-
ticipate in the IRF7 pathway through the phosphorylation of
IRAK-1.
It is believed that activation of IRF7 is also regulated by
its phosphorylation (36, 37). A previous study demonstrates
that two IKK-related kinases, TANK-binding kinase 1
(TBK1) and inducible IKK (IKKi) are involved in phos-
phorylation of IRF7 as well as IRF3 (38, 39). TBK1 /  cells
failed to produce type I IFNs in response to TLR3 and
TLR4 stimuli (40–43). Nevertheless, we found that IFN- 
production in response to CpG ODN in pDCs derived from
mice deficient in TBK1 or IKKi was not impaired compared
with that of wild-type cells (28). Although further studies us-
ing mice lacking both TBK1 and IKKi will be required to
Figure 5. Impaired nuclear translocation of IRF7 in response to 
D35 in Irak-1 /Y cells. (A) Flt3L–BMDCs from Irak-1 /Y and Irak-1 /Y 
mice were stimulated with D35 for 1, 2, or 6 h. Nuclear proteins were pre-
pared and subject to immunoblot analysis using anti-IRF7 and anti-RelA. 
An asterisk shows IRF7 protein. (B) Flt3L–BMDCs from Irak-1 /Y and Irak-1 /Y 
mice were stimulated with D35 for 10, 30, or 60 min. Whole cell lysates 
were subject to immunoblot analysis using antiphospho-specific ERK1 
and anti-ERK1. (C) Schematic illustration of TLR7- and TLR9-mediated sig-
naling pathway. IRF7 interacts with MyD88 to form a complex, which pro-
vides the foundation for the induction of the IFN- . IRAK-1 binds to IRF7 
directly and is included in this complex. IRAK-1 is dispensable for the NF- B 
activation but specifically regulates the IFN-  induction through the acti-
vation of IRF7. IRAK-4 may locate upstream of IRAK-1 and be involved in 
the activation of IRAK-1.JEM VOL. 201, March 21, 2005 921
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exclude the possibility of redundancy (44), it is more plausi-
ble to believe that other kinases are involved in TLR7 and
TLR9 signaling. On the other hand, it is reported that IRF7
is activated by the MAPK kinase 4 (MKK4)–c-Jun NH2-ter-
minal kinase (JNK) pathway in response to UV and chemo-
therapeutic agents, which induce DNA damage (45). These
observations imply that activation of IRF7 can occur down-
stream of MAPK cascades in response to some stimuli.
However, the MAPK activation in response to TLR9
ligands was not impaired in Irak-1 /Y pDC, suggesting that
another pathways are responsible for the activation of IRF7.
In the present study, we showed that IRAK-1 phosphor-
ylated IRF7 in vitro and the expression of IRAK-1 KN sup-
pressed the activation of the IFN- 4 promoter induced by
coexpression of MyD88 and IRF7. These data suggest that
IRAK-1 might serve as a kinase for IRF7. However, we
could not show endogenous phosphorylation of IRF7 by
IRAK-1 because these experiments were technically difficult
for small amounts of IRF7 expression and stimulus-depen-
dent degradation of IRAK-1. Moreover, previous studies
have suggested that introduction of IRAK-1 KN into
IRAK-1–deficient 293 cells can reconstitute responsibilities
to IL-1 (35). Therefore, the possibility that the kinase activ-
ity of IRAK-1 is dispensable for IRF7 activation cannot be
ruled out. Further studies will be required to clarify whether
the kinase activity of IRAK-1 is necessary and sufficient for
its function using IRAK-1 KN–expressing pDCs.
In conclusion, our present study showed that IRAK-1 is
a key regulator for TLR7- and TLR9-mediated IFN-  pro-
duction in pDCs. These results provide possibilities that
IRAK-1 would be an interesting therapeutic target for spe-
cific regulation of IFN-  production, which leads to the
treatment of viral infection and autoimmune diseases.
MATERIALS AND METHODS
Plasmids. The IFN- 4 promoter construct and endothelial leukocyte ad-
hesion molecule (ELAM) promoter construct have been described previ-
ously (28). FLAG–IRF7, the series of deletion mutant of IRF7 and
TRAF6c were described previously (28). Plasmids encoding fusion proteins
IRF7–CFP, IRAK-1–CFP, IRAK-4–CFP, IRF7–YFP, IRAK-1–YFP,
and IRAK-4–YFP were constructed essentially as described previously (28).
The COOH-terminal portion of IRF7 was obtained by PCR and was li-
gated into the EcoRI and SalI sites of pGEX-5X1 vector (Amersham Bio-
sciences). The cDNA fragments encoding IRAK-1 and IRAK-4 were am-
plified by PCR from a human spleen cDNA library (CLONTECH
Laboratories, Inc.), digested with appropriate restriction enzymes, and in-
serted into pFLAG–CMV2 (Sigma-Aldrich) or pCMV-Myc (CLON-
TECH Laboratories, Inc.). To generate a kinase-negative mutant of human
IRAK-1 (K239A) and IRAK-4 (K213/214A), site-directed mutagenesis us-
ing QuickChange XL-site directed mutagenesis kit was performed as speci-
fied by the manufacturer (Stratagene). The sequences of DNA fragments
obtained by PCR were confirmed by DNA sequencing.
Mice. Irak-1 /Y mice were provided by Dr. J.A. Thomas (University of
Texas Southwestern Medical Center, Dallas, TX; 18).
Cells and reagents. Flt3L–BMDCs were prepared as described previously
(24). CpG oligodeoxynucleotides (D35 and ODN1668) were prepared as
described previously(24). R-848 was provided by the Pharmaceuticals and
Biotechnology Laboratory, Japan Energy Corporation (9). Poly(I/C) was
purchased from Amersham Biosciences, Inc. Anti-IRF7, anti-ERK, and
anti-phosphorylated-ERK were obtained from Zymed Laboratories and
New England Biolabs, Inc., respectively.
Transfection, immunoprecipitation, and immunoblot analysis.
HEK293 cells (106) were seeded on a 100-mm dish. Cells were transiently
transfected 12 h later with a total of 6.0  g of various plasmids with Lipo-
fectamine 2000 (Invitrogen). Immunoprecipitation and immunoblot analy-
sis were done as described previously (28).
FRET. HEK293 cells plated on a collagen-coated glass dish were imaged
as described previously (28). In brief, cells were imaged on an inverted mi-
croscope equipped with a cooled CCD camera, and controlled by Meta-
Morph software (Universal Imaging Corp.). A pair of proteins fused to YFP
or CFP was expressed in HEK293 cells. Cells were imaged by the use of the
following filter sets: an MX0420 excitation filter and a BP470-490 emission
filter (Olympus) for the CFP images, an MX0420 excitation filter and a
535DF35 emission filter (Omega Optical, Inc.) for the FRET images, and a
510DF23 excitation filter (Omega Optical, Inc.) and a 560DF15 emission
filter (Omega Optical, Inc.) for the YFP images. An XF2052 dichroic mir-
ror (Omega Optical, Inc.) was used throughout the experiments. Exposure
times were 200 msec for CFP and FRET images, and 100 msec for YFP
images. After the data acquisition, the average intensities of CFP, FRET,
and YFP were measured and calculated the fluorescence through the FRET
filter set consisted of a FRET component (“corrected” FRET, FRETC).
The non-FRET components were subtracted as described previously (28).
For our experimental conditions, we used the following equation: FRETC  
FRET   (0.34   CFP)   (0.02   YFP).
For flow cytometric analysis of FRET, HEK293 cells transfected with
CFP and/or YFP fusion proteins as described above were resuspended in
293 expression media (Invitrogen) and measured YFP (excitation: 488 nm;
emission: 530 nm), CFP (excitation: 407 nm; emission: 510 nm), FRET
(excitation: 407 nm; emission: 535 nm) by using FAC aria (Becton Dickin-
son) and BD FACSDiVa software. FRET is shown as YFP emission ob-
tained by CFP excitation divided by CFP emission by CFP excitation.
Luciferase reporter assay. HEK293 cells seeded on 24-well plates (105
cells/well) were transiently transfected with 100 ng of the luciferase reporter
plasmid together with a total of 900 ng of various expression vectors. Then,
36 h later, the luciferase activity in the total cell lysates was measured with
Dual-luciferase reporter assay system (Promega). Renilla luciferase reporter
gene (50 ng) was simultaneously transfected as an internal control.
ELISA. Flt3-BMDCs (106 cells/well) were stimulated for 24 h with various
concentration of CpG oligonucleotide D35 and ODN1668. Concentra-
tions of TNF- , IL-6, IL-12 p40, and IFN-  in the culture supernatant
were measured by ELISA according to manufacturer’s instructions (Gen-
zyme for TNF-  and IL-12 p40, R&D for IL-6 and PBL Bio Lab for IFN- ).
Serum cytokine concentrations of IFN-  and IL-12 p40 were also deter-
mined by ELISA.
In vitro kinase assay. Two million HEK-293 cells were seeded on a 60-
mm-diam dish. 24 h later, cells were transiently transfected with a total of
5.0   g of empty or the indicated plasmids (2.0  g of pFLAG-CMV2
IRAK-1 or IRAK-1, 4.0  g of pFLAG-CMV2 IRAK-4 or IRAK-4 KN),
using Lipofectamine 2000 as specified by the manufacturer (Invitrogen).
Cells were harvested 36 h after transfection, lysed, and then immunoprecip-
itated with protein G–Sepharose together with 1.0  g of anti-FLAG M2
mAb (Sigma-Aldrich) for 12 h by rotation. The beads were washed four
times with lysis buffer, and another three times with kinase assay buffer (20
mM Hepes, pH 7.5, 20 mM MgCl2, 3 mM MnCl2, and 10 mM  -glycero-
phosphate). The immunoprecipitants were incubated with 2.0  g GST-
IRF7 and 10 mCi [ -32P] ATP (Amersham Biosciences) at 30 C for 30
min. Kinase reactions were stopped by addition of Laemmli sample buffer,IRAK-1 REQUIREMENT FOR TLR7- AND TLR9-MEDIATED IFN-  INDUCTION | Uematsu et al. 922
and were separated on a 4 to 20% poly acrylamide gradient gel. Gel was de-
tained, dried, and exposed to X-ray film.
Flow cytometry. For intracellular IFN-  and IL-12p40 staining, Flt3L-
DCs were treated with 3  M D35 and cultured for 5 h. Golgi stop (BD
Biosciences) was added for an additional 3 h and cells were collected and
fixed in paraformaldehyde. Staining for IFN-  was performed in saponin-
containing buffer using a mixture of rat anti–mouse IFN-  (clone F18,
Hycult Biotechnology b.v., and clone RMMA-1; PBL Biomedical Labora-
tories), followed by biotinylated mouse anti–rat IgG (Jackson ImmunoRe-
search Laboratories), and Streptavidin-APC (BD Biosciences; 46). Staining
for IL-12 was performed in saponin-containing buffer using anti–IL-12–PE
(BD Biosciences). Cells were subsequently stained with anti-CD11c-FITC
(clone HL3) and anti-B220–cychrome (clone RA3-6B2), and analyzed on a
FACSCalibur (BD Biosciences).
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